Fatty Liver Disease (NAFLD/MASLD): Symptoms, Stages & Treatment

Fatty Liver Disease (NAFLD/MASLD): Symptoms, Stages & Treatment

Fatty liver disease — now officially called Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD), previously known as NAFLD — is a condition where excess fat accumulates in the liver unrelated to alcohol use. It is the most common liver disease in the world and affects an estimated 50% or more of the adult population in Mexico. In my practice at Centro Médico González in Mexicali, I see this condition at every stage, from simple fat accumulation discovered incidentally on an ultrasound to advanced cirrhosis requiring liver transplant evaluation. The good news: when detected early, fatty liver disease is reversible. The critical issue is that most patients have no symptoms until significant damage has already occurred.

What Is Fatty Liver Disease? Understanding MASLD and MASH

Fatty liver disease exists on a spectrum. The medical community updated the terminology in 2023 to reflect the underlying metabolic drivers of the disease:

• MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease): The new term for NAFLD. Defined by the presence of ≥5% liver steatosis (fat) on imaging or biopsy, plus at least one cardiometabolic risk factor (obesity, type 2 diabetes, hypertension, dyslipidemia, or metabolic syndrome).
• MASH (Metabolic dysfunction-Associated Steatohepatitis): The new term for NASH. This is the more serious inflammatory form of the disease, previously called nonalcoholic steatohepatitis. MASH involves hepatocyte injury, inflammation, and ballooning in addition to fat accumulation.

Why the Name Change Matters

The name change from NAFLD to MASLD is not cosmetic. It emphasizes that this disease is metabolic in origin — driven by insulin resistance, obesity, type 2 diabetes, and cardiovascular risk factors. Understanding this framing helps patients and physicians focus treatment where it belongs: on the metabolic syndrome, not just the liver.

Who Is at Risk?

In Mexico, the convergence of high rates of obesity, type 2 diabetes, and metabolic syndrome creates a nearly perfect storm for MASLD. According to consensus data from the Revista de Gastroenterología de México, the prevalence of fatty liver disease in Mexico is estimated at over 50% of the general population. Among obese patients undergoing bariatric surgery, the prevalence reaches 82%. In patients with type 2 diabetes, it is confirmed in 18.5% of cases through biopsy.

Risk factors include: - Obesity, especially central (abdominal) adiposity - Type 2 diabetes or insulin resistance - Dyslipidemia (high triglycerides, low HDL) - Hypertension - Metabolic syndrome - Hypothyroidism - Polycystic ovary syndrome (PCOS) - Rapid weight loss or total parenteral nutrition (rare)

The Stages of Fatty Liver Disease: From Steatosis to Cirrhosis

Understanding the progression of fatty liver disease is essential for treatment decisions. There are four recognized fibrosis stages, graded using the METAVIR scoring system:

Stage F0 — No Fibrosis (Simple Steatosis)

Fat is present in the liver (≥5% of hepatocytes), but there is no inflammation and no scarring. This stage is entirely reversible with lifestyle changes. It is often found incidentally on abdominal ultrasound ordered for another reason. Most patients at this stage feel completely normal.

Stage F1 — Mild Fibrosis (Portal Fibrosis Without Septa)

Some scar tissue begins to form around the portal tracts. Inflammation may be present. Still a reversible stage with sustained lifestyle intervention. FIB-4 scores at this stage typically range from 1.12 to 1.34.

Stage F2 — Moderate Fibrosis (Few Septa Present)

Fibrosis has extended beyond the portal tracts and early bridging septa are visible. This is the threshold at which resmetirom (Rezdiffra™), the first FDA-approved drug for MASH, becomes eligible — specifically approved for patients with MASH and stage F2 or F3 fibrosis without cirrhosis. FIB-4 values around 1.85 are typical.

Stage F3 — Advanced Fibrosis (Numerous Septa, No Cirrhosis)

Significant scarring exists across the liver. Portal hypertension may begin to develop. Surveillance for hepatocellular carcinoma (HCC) becomes a priority. This is a high-risk stage requiring specialist management. Reversal is still possible but requires aggressive, multidisciplinary intervention.

Stage F4 — Cirrhosis

Extensive scarring has distorted the liver architecture. Cirrhosis from MASH is now one of the leading indications for liver transplantation in the United States and is rapidly rising in Mexico. FIB-4 scores above 3.48 are associated with F4 fibrosis (cirrhosis) with high specificity. Once decompensation occurs — variceal bleeding, ascites, hepatic encephalopathy, or jaundice — liver transplant evaluation should begin promptly.

Recognizing Symptoms: Why Fatty Liver Disease Is Called a "Silent" Disease

The majority of patients with MASLD at stages F0 through F2 have no symptoms at all. This is what makes the disease dangerous: by the time symptoms appear, significant damage may have already occurred.

Early Symptoms (Often Absent or Subtle)

When symptoms do appear in early stages, they may include: - Fatigue or unexplained tiredness - Mild discomfort or heaviness in the upper right abdomen - Elevated liver enzymes (ALT, AST) found on routine bloodwork - Fatty liver appearance on ultrasound

Symptoms of Advanced Disease (F3–F4)

As fibrosis advances toward cirrhosis, more definitive symptoms emerge: - Jaundice: yellowing of the skin and eyes - Ascites: accumulation of fluid in the abdomen, causing bloating - Edema: swelling in the legs and ankles - Easy bruising or bleeding: due to impaired clotting factor synthesis - Spider angiomas: small spider-shaped blood vessel clusters on the skin - Confusion or cognitive changes (hepatic encephalopathy) - Varices: dilated veins in the esophagus or stomach that can rupture and bleed

In my clinical experience, I regularly see patients who assumed their fatigue was due to stress or poor sleep — only to discover on evaluation that they had advanced hepatic fibrosis. Early screening is essential, particularly for anyone with metabolic risk factors.

Diagnosing Fatty Liver Disease: Tests and Scores

Blood Tests

Standard liver function tests (ALT, AST, GGT, bilirubin, albumin, INR) provide a basic window into liver health but do not stage fibrosis reliably. More useful are:

• FIB-4 Index: Calculated from age, AST, ALT, and platelet count. A value below 1.67 effectively rules out advanced fibrosis; above 3.48 is highly specific for cirrhosis (F4). This is my first-line non-invasive assessment tool.
• NAFLD Fibrosis Score: Another non-invasive calculator incorporating BMI, glucose levels, and platelet count.

Imaging

• Abdominal Ultrasound: First-line imaging. Detects moderate-to-severe steatosis well, but cannot reliably stage fibrosis.
• FibroScan (Transient Elastography): Measures liver stiffness as a surrogate for fibrosis. Non-invasive, painless, and highly useful for monitoring disease progression.
• MRI-PDFF: The most accurate non-invasive method for quantifying liver fat. Used in clinical trials and research settings.

Liver Biopsy

Liver biopsy remains the gold standard for definitive staging of fibrosis and assessment of MASH activity. It provides direct histological evaluation using the METAVIR scoring system (F0–F4) and the NAS (NAFLD Activity Score) for grading inflammation. We typically recommend biopsy when non-invasive tests are inconclusive, particularly in patients where the distinction between F2 and F3 changes treatment decisions.

Treatment of Fatty Liver Disease: A Staged Approach

The treatment strategy depends on fibrosis stage, presence of MASH, and coexisting metabolic conditions.

Lifestyle Modification: The Foundation of All Treatment

For all stages of MASLD, sustained weight loss is the most effective intervention. Evidence consistently shows that losing 7–10% of body weight reduces liver steatosis, inflammation, and, in some studies, fibrosis. The mechanism is straightforward: reducing insulin resistance reduces hepatic fat delivery.

Key lifestyle components: - Diet: Mediterranean-style diet is the best-studied. Reducing refined carbohydrates, sugar, and saturated fats while increasing fiber, olive oil, and vegetables. Avoiding high-fructose corn syrup is particularly important, as fructose is directly converted to liver fat. - Physical activity: Both aerobic exercise (at least 150 minutes/week of moderate intensity) and resistance training independently reduce hepatic steatosis. - Alcohol avoidance: Even modest alcohol intake accelerates progression in MASLD/MASH. - Coffee consumption: Multiple studies have shown an association between habitual coffee consumption (3+ cups/day) and slower fibrosis progression in NAFLD.

Pharmacological Treatment

Until 2024, there was no approved drug specifically for MASH. That changed in March 2024 when the FDA approved resmetirom (Rezdiffra™) for adults with MASH and stage F2 or F3 fibrosis. Resmetirom works by selectively activating the thyroid hormone receptor beta (THR-β) in the liver, accelerating the metabolism of liver fat. This is the first drug in a new class called thyroid hormone receptor beta agonists.

Additional pharmacological agents I commonly use in my practice, depending on the patient profile, include: - GLP-1 receptor agonists (semaglutide, tirzepatide): Approved for diabetes and obesity, these medications produce substantial weight loss and have shown significant improvements in liver histology in clinical trials. Multiple outcome trials are ongoing. - Vitamin E (800 IU/day): Recommended by AASLD guidelines for non-diabetic adults with biopsy-proven MASH. Modest anti-inflammatory effect. - Pioglitazone: Approved for type 2 diabetes; has shown improvement in NASH histology in clinical trials, particularly in patients with insulin resistance or diabetes. - Statins: Safe in MASLD and important for cardiovascular risk reduction (which is the leading cause of death in MASLD patients). Do not worsen liver disease.

Bariatric Surgery for Obese Patients With MASLD

For patients with obesity (BMI ≥35, or ≥30 with metabolic comorbidities), bariatric surgery is a highly effective intervention that produces sustained weight loss and frequently reverses NASH histology, including fibrosis regression. Sleeve gastrectomy and Roux-en-Y gastric bypass are the most commonly performed procedures. In Mexico, bariatric surgery is accessible and well-established; as a hepatobiliary surgeon at Centro Médico González in Mexicali, I collaborate closely with bariatric surgery colleagues when this is the appropriate intervention for a patient.

Surgical Management of Complications

As MASLD progresses to cirrhosis, surgical and endoscopic management of complications becomes necessary:

• Variceal banding or sclerotherapy: For esophageal varices at risk of bleeding (managed endoscopically).
• TIPS (Transjugular Intrahepatic Portosystemic Shunt): For refractory ascites or variceal bleeding not controlled endoscopically.
• Hepatocellular carcinoma (HCC) resection or ablation: MASLD-associated cirrhosis is a major risk factor for liver cancer. Dr. César Eduardo González Muñoz performs both surgical resection and is experienced in the multidisciplinary management of HCC.
• Liver transplantation: For decompensated cirrhosis or HCC within Milan criteria, liver transplant is the definitive treatment.

When Is Liver Transplant Needed for Fatty Liver Disease?

MASH-associated cirrhosis has become one of the leading indications for liver transplantation in North America, and the trend in Mexico mirrors this globally. Transplant evaluation is indicated when:

• MELD score ≥15: The Model for End-Stage Liver Disease score estimates 3-month mortality and prioritizes waitlist allocation.
• Decompensation: First episode of ascites, variceal bleeding, hepatic encephalopathy, or spontaneous bacterial peritonitis.
• HCC within transplant criteria: Liver cancer arising on cirrhotic background, within Milan or UCSF criteria.
• Intractable hepatic hydrothorax or other refractory complications.

An important consideration after liver transplant for MASH cirrhosis is disease recurrence: steatosis returns in over 80% of transplant recipients, and steatohepatitis recurs in approximately 33% of cases, particularly if the underlying metabolic syndrome is not addressed. Long-term management includes continued lifestyle modification and metabolic risk factor control after transplant.

I lead the liver transplant program at our center in Mexicali. Our clinic is located just 5 minutes from the Calexico, CA border crossing, making us directly accessible to patients from Imperial Valley, San Diego, Los Angeles, and across Southern California seeking high-quality transplant evaluation and care.

Managing the Metabolic Syndrome: The Heart–Liver Connection

A critical point that is often overlooked: cardiovascular disease is the leading cause of death in patients with MASLD, not liver disease. Most patients with fatty liver have coexisting hypertension, dyslipidemia, and insulin resistance that dramatically increase their cardiovascular mortality risk.

Treatment of fatty liver disease must therefore be integrated with: - Optimal blood pressure control (target <130/80 mmHg in patients with MASLD) - Statin therapy for dyslipidemia (safe in MASLD, cardioprotective, does not worsen liver disease) - HbA1c management in diabetic patients (target <7.0%, or individualized) - Smoking cessation

Dr. César Eduardo González Muñoz works as part of a multidisciplinary team including cardiologists, diabetologists, and nutritionists to ensure that every aspect of a patient's metabolic profile is addressed in parallel with their liver disease management.

Long-Term Monitoring: Follow-Up After Diagnosis

The follow-up schedule for MASLD depends on the fibrosis stage:

Low Risk (F0–F1, FIB-4 <1.67)

Intermediate Risk (F2–F3)

High Risk (F4 — Cirrhosis)

Frequently Asked Questions About Fatty Liver Disease

What is the difference between fatty liver and NASH (now called MASH)?

Simple fatty liver (MASLD without MASH) means fat is present in the liver without significant inflammation or cell damage. MASH — previously called NASH — means there is active inflammation, hepatocyte ballooning, and injury in addition to fat. MASH is the form that progresses to fibrosis, cirrhosis, and liver failure. A liver biopsy or advanced non-invasive scoring is required to distinguish between the two.

Can fatty liver disease be reversed?

Yes — at stages F0 through F2, fatty liver disease is reversible with sustained lifestyle changes, primarily weight loss of 7–10% of body weight. Even fibrosis at F3 can partially regress with aggressive treatment. F4 (cirrhosis) involves irreversible architectural changes, though complications can be managed and progression slowed.

Is fatty liver disease dangerous if I have no symptoms?

Yes. This is the critical danger of MASLD — the majority of patients have no symptoms until the disease is at an advanced stage. Routine screening with liver function tests and abdominal ultrasound is recommended for anyone with obesity, type 2 diabetes, or metabolic syndrome, regardless of symptoms.

What should I eat if I have fatty liver disease?

The Mediterranean diet is the most evidence-backed dietary pattern for MASLD. Focus on olive oil, vegetables, legumes, fish, and whole grains. Strictly reduce or eliminate sugary beverages, high-fructose corn syrup, refined carbohydrates, and red meat. Avoid all alcohol, as even moderate intake can accelerate liver damage.

Does fatty liver disease lead to liver cancer?

It can. Once MASLD has progressed to cirrhosis (F4), there is a significant annual risk of hepatocellular carcinoma (HCC), the most common primary liver cancer. This is why patients with MASH-related cirrhosis require HCC surveillance every 6 months with liver ultrasound. Early detection of HCC allows curative surgical resection or ablation.

When does fatty liver disease require liver transplant?

Liver transplant is considered when MASH-related cirrhosis has decompensated — meaning the liver can no longer perform its vital functions adequately. Decompensation signals include ascites (abdominal fluid), variceal bleeding, hepatic encephalopathy, or jaundice. Transplant evaluation should begin when MELD score is ≥15 or at first decompensation.

Can fatty liver disease come back after liver transplant?

Yes. Steatosis (fat recurrence) occurs in more than 80% of liver transplant recipients for MASH cirrhosis because the metabolic syndrome — the root cause — persists in the body even after the diseased liver is replaced. Steatohepatitis recurs in approximately one-third of patients. Addressing obesity, diabetes, and lipid disorders after transplant is essential.

Is exercise alone enough to treat fatty liver disease?

Exercise is beneficial and reduces hepatic fat, but it is most effective when combined with caloric restriction for patients who need to lose weight. Aerobic exercise and resistance training both reduce liver steatosis through different mechanisms. For patients with advanced fibrosis or MASH, exercise alone is typically insufficient and pharmacological treatment is added.

Take the Next Step: Evaluation at Centro Médico González, Mexicali

If you have been told you have fatty liver, elevated liver enzymes, or have risk factors like obesity, type 2 diabetes, or metabolic syndrome — early evaluation is the most important step you can take. At Centro Médico González, located minutes from the California border in Mexicali, Baja California, Dr. César Eduardo González Muñoz provides comprehensive hepatobiliary evaluation, advanced non-invasive fibrosis staging, and personalized treatment planning across every stage of fatty liver disease. For patients who have progressed to advanced cirrhosis, our center also offers liver transplant evaluation and surgical management of hepatic complications.

To schedule a consultation, call +52-686-338-3848 or visit our clinic at C. I 1701, entre Calle Zaragoza y Calle Vicente Guerrero, 21100 Mexicali, B.C. — just 5 minutes from the Calexico, CA port of entry.

Contact & Clinic Location

Clinic Address: Plaza Zaragoza, Calle I #1701, between Zaragoza & Vicente Guerrero, Col. Nueva, 21100 Mexicali, B.C., México.

Phone: (686) 338-3848

Office Hours: Monday to Saturday: 9AM - 7PM

Request Consultation & Guidance

Complete the form below to contact our clinical coordinator directly.